Non binding, unofficial English translation for information purposes only.
Original in French.

CELLECTIS
A French limited liability company (*société anonyme*) with share capital of €2,124,456.65

Registered Office: 8, rue de la Croix Jarry - 75013 Paris
Paris Trade and Companies Register No. 428 859 052

(the "Company")

COMBINED SHAREHOLDERS' MEETING OF NOVEMBER 4, 2020

AGENDA

Agenda of the ordinary shareholders' meeting

1. Appointment of a new board member.

Agenda of the extraordinary shareholders' meeting

2. Amendment of the age limit applicable to directors, the chairman of the board of directors, the chief executive officer and to the deputy chief executive officers – subsequent amendment of the articles of association.

--ooOoo--

Conditions for attending the General Meeting

Any shareholder, regardless of the number of shares owned, may attend this General Meeting.

The right to participate in the meeting shall be evidenced by the registration of the shares in the name of the shareholder or of the intermediary registered on his behalf, at midnight, Paris time, on November 2, 2020, either in the registered share accounts held by Société Générale or in the bearer share accounts held by an authorized custodian.

The registration of shares in the bearer share accounts held by an authorised intermediary is evidenced by a certificate of participation issued by the latter, attached to the remote voting form or proxy form or on behalf of the shareholder represented by the registered intermediary.

Due to the Covid-19 pandemic, this general meeting will take place in camera, i.e. without the physical presence of the shareholders and the other persons entitled to stand. The shareholders will therefore not be able to physically attend said meeting.

Under these conditions, shareholders are invited to vote remotely, prior to the general meeting, by giving a proxy to the chairman or to any other natural or legal person of their choice, or by returning the postal voting form.

Exceptionally, we invite you not to give a proxy to a third party to represent you at the meeting insofar as the meeting will be held without the physical presence of the shareholders and therefore of any third party proxies, and to give preference to voting by mail or to give a proxy to the chairman.

Shareholders wishing to vote by mail, on the Internet or give proxy to the chairman:

for registered shareholders: send the single voting form by post or by proxy, which will be sent to him with the convening notice, either by ordinary mail using the prepaid envelope attached to the notice or by e-mail to the following address: agm@cellectis.com no later than November 1st, 2020;

for the holder of bearer shares: ask for this form from the intermediary who manages his shares, as of the date of notice of the meeting. The single voting form by post or by proxy must be accompanied by a certificate of participation issued by his financial intermediary and returned by the latter either by mail to the following address: Société Générale - Service assemblées – 32 Rue du Champ de Tir, CS 30812, 44308 Nantes Cedex 3 or by e-mail to the following address: agm@cellectis.com no later than November 1st, 2020.

Requests for the voting form must reach Société Générale via the shareholder's financial intermediary at one of the addresses indicated above, at least six days before the date of the meeting.

Only duly completed voting forms that are received at Société Générale at one of the addresses indicated above at least three days before the scheduled date of the meeting, i.e. no later than November 1st, 2020, and accompanied by the certificate of participation issued by an authorised intermediary for bearer shares will be taken into account.

Shareholders wishing to give proxy to a third party:

In accordance with Article R.225-79 of the French Commercial Code, the notification of the appointment and revocation of a proxy representative can be made electronically, as follows:

for registered shareholders: send an email to the following address: assemblees.generales@sgss.socgen.com specifying one's full name, address and Société Générale identifier for directly registered shareholders (information available at the top left of the account statement) or his identifier with his financial intermediary if he is a holder of administered registered shares and the full name and address of the appointed or revoked agent;

for holders of bearer shares: send an email to the following address: assemblees.generales@sgss.socgen.com specifying their full name, address and bank details as well as the full name and address of the appointed or revoked representative. The shareholder must then imperatively ask the financial intermediary that manages his account to send written confirmation to Société Générale, Service Assemblées, 32 Rue du Champ de Tir, CS 30812, 44308 Nantes Cedex 3.

To be taken into account, the notifications of appointment or revocation of a proxy, duly completed and signed, must reach the Company or Société Générale at the latest:

- the day prior to the meeting, i.e. on November 3rd, 2020 if sent by email,

- three days prior to the meeting, i.e. November 1st, 2020 if made by post.

The proxy holder sends his voting instructions for the exercise of his mandates in the form of a scanned copy of the single form, to Société Générale, by email to the following address: assemblees.generales@sgss.socgen.com.

The form must bear the surname, first name and address of the proxy, the words "As a proxy holder" and must be dated and signed. Voting directions are indicated in the box "I vote by correspondence" of the form.

He attaches a copy of his identity card and, where appropriate, a power of representation for the person morality that he represents.

To be taken into account, the email shall reach Société Générale at the latest on the fourth day prior to the date of the meeting, i.e. on October 29th, 2020.

In addition, for its own voting rights, the proxy sends its voting instructions in accordance with the usual procedures.

It is stipulated that any shareholder having already cast his vote or sent a proxy:

- in application of decree n° 2020-418 of 10 April 2020 adapting the rules for meeting and deliberation of meetings due to the pandemic of Covid-19, by way of derogation from III of article R. 225-85 of French Commercial Code, may choose another mode of participation in the meeting provided that its instruction in this sense reaches Société Générale: ag2020.fr@socgen.com within the legal deadlines, specifying that it is 'a new instruction which cancels and replaces the previous one. By way of derogation from the second sentence of article R. 225-80 of this Code, the previous instructions received are then revoked,

- may at any time transfer all or part of his shares. If the transfer takes place before November 2nd, 2020 at midnight Paris time, the Company will invalidate or amend, accordingly the postal vote, proxy, or certificate of participation. For this purpose, the authorized financial intermediary shall notify the Company or its agent of the transfer and forward the necessary information.

Requests to add draft resolutions or items to the agenda

Requests to add draft resolutions or items to the agenda of the general meeting fulfilling the conditions provided for by Articles L.225-105, R.225-71, and R.225-73 of the French Commercial Code, presented by shareholders, must, in accordance with the legal provisions, reach Cellectis, 8 rue de la Croix Jarry – 75013 Paris, by registered letter with acknowledgement of receipt or by electronic communication at the following address agm@cellectis.com, no later than the twenty-fifth day preceding the date of the general meeting.

These requests must be accompanied by a registration certificate that justifies the possession or the representation by the authors of the request of the proportion of the capital required by Article R.225-71 above. In addition, the examination by the general meeting of the items or draft resolutions filed by the shareholders in accordance with the regulations is subject to the submission by the authors of the request of a new certificate justifying the registration of their shares under the same conditions by the second business day preceding the meeting.

The texts of the draft resolutions submitted by the shareholders and the list of items added to the agenda at their request will be posted on the Company's website **www.cellectis.com** as soon as the aforementioned conditions are fulfilled.

Questions in writing

Any shareholder may also formulate a written question. These questions should be addressed:

- to the head office at 8, rue de la Croix Jarry - 75013 Paris by registered letter with acknowledgement of receipt, addressed to the chairman of the board of directors,

- to the following email address agm@cellectis.com;

at the latest four business days before the general meeting, i.e. on October 29th, 2020, accompanied by a certificate of registration either in the registered securities accounts or in the bearer securities accounts kept by the authorised intermediary.

Furthermore, insofar as the general meeting is held without the physical presence of the shareholders, it is recalled that shareholders will not be able to ask oral questions or propose new resolutions during the general meeting. However, written questions from shareholders that are sent to the Company after the deadline provided for by the regulatory provisions but before the general meeting via the above-mentioned address agm@cellectis.com will be processed in the as far as possible.

This meeting notice constitutes notice of the meeting provided that no changes are made to the agenda and resolutions, in particular following requests for the registration of draft resolutions presented by shareholders.

The board of directors

--ooOoo--

CELLECTIS
A French limited liability company (*société anonyme*) with share capital of €2,124,456.65

Registered Office: 8, rue de la Croix Jarry - 75013 Paris
Paris Trade and Companies Register No. 428 859 052

(the "Company")

COMBINED SHAREHOLDERS' MEETING OF NOVEMBER 4, 2020

TEXT OF RESOLUTIONS

FIRST RESOLUTION
Appointment of a new board member.

The General Meeting, ruling under the conditions of quorum and majority required for ordinary general meetings,

having considered the report of the board of directors,

appointed Mr. Jean-Pierre Garnier as new board member for a term of office of three (3) years, expiring at the annual general meeting held to approve the financial statements for the year ending December 31, 2022.

Mr. Jean-Pierre Garnier indicated in advance that he would accept this term of office as director and was not subject to any incompatibility that might prevent him from exercising it.

SECOND RESOLUTION
Amendment of the age limit applicable to directors, the chairman of the board of directors, the chief executive officer and to the deputy chief executive officers – subsequent amendment of the articles of association.

The General Meeting, ruling under the conditions of quorum and majority required for extraordinary general meetings,

having considered the report of the board of directors,

resolved to amend the age limit applicable to directors, the chairman of the board of directors, the chief executive officer and to the deputy chief executive officers in order to bring it from 70 to 75 years and as a consequence to amend:

(i) the last paragraph of article 11.1. of the articles of association as follows:

"The number of directors over the age of 75 shall not exceed one-third of the directors in office. If this limit is exceeded during the directors' terms of office, the oldest director shall automatically be deemed to have resigned at the end of the next ordinary general shareholders' meeting."

(ii) the last paragraph of article 11.2. of the articles of association as follows:

"The Chairman of the Board cannot be more than 75 years old. If the Chairman reaches this age limit during his term of office as Chairman, he shall automatically be deemed to have resigned at the end of the current office. Subject to this provision, the Chairman of the Board is always eligible for reappointment."

(iii) article 14.1.2. of the articles of association as follows:

"The Chief Executive Officer cannot be more than 75 years old. If the Chief Executive Officer reaches this age limit, he shall automatically be deemed to have resigned. However, the Chief Executive Officer's term of office shall be prolonged until the next Board of Directors meeting, at which a new Chief Executive Officer shall be appointed."

(iv) the fifth paragraph of article 14.2.1. of the articles of association as follows:

"Deputy Chief Executive Officers cannot be more than 75 years old. If a Deputy Chief Executive Officer in office reaches this age limit, he shall automatically be deemed to have resigned. The Deputy Chief Executive Officer's term of office shall be prolonged until the next Board of Directors' meeting, at which a new Deputy Chief Executive Officer may be appointed."

--ooOoo--

OVERVIEW

YEAR ENDING DECEMBER 31st 2019

Situation of the Company and its subsidiaries and activities for the financial year ending December 31st 2019

Cellectis S.A. (hereinafter “Cellectis”, the "Company" or “we”) is a limited liability company (“*société anonyme*”) registered in France whose head office is in Paris. Our product candidates, based on gene-edited T-cells that express chimeric antigen receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancers. We believe that immunotherapy based on CARs is one of the most promising fields of research in the fight against cancer. Our gene-editing technologies allow us to create allogeneic CAR T-cells (that we call "UCART"), meaning they are derived from healthy donors rather than the patients themselves. We believe that the production of allogeneic CAR T-cells enables us to develop off-the-shelf profitable products which can be cryopreserved, inventoried and distributed throughout the world. Our expertise in editing the human genome allows us to develop candidate products showing new safety and efficacy characteristics, including control properties designed to prevent them from attacking healthy tissue, enabling them to tolerate oncology treatments and equipping them to resist mechanisms that inhibit the actions of the immune system. In addition to our focus on immuno-oncology, we are also exploring the use of new gene-editing technologies in other therapeutic applications, as well as, through our subsidiary Calyxt, Inc., to develop healthier food products for a growing population.

Cellectis is listed since 2007 on the Euronext Growth Market of Euronext Paris ("Euronext Growth"). In March 2015, Cellectis completed a public offering of 5.5 million American Depositary Shares ("ADS") on the Nasdaq Global Market ("Nasdaq") raising gross proceeds of $228.2 million. In April 2018, Cellectis completed a secondary offering of 6,146,000 ADS at a price of $31.00 per ADS, raising gross proceeds of $190.5 million.

The financial statements of the Company for the financial year ended December 31, 2019 include Cellectis and its three subsidiaries located in the United States, Cellectis, Inc., Cellectis Biologics, Inc. (incorporated on January 18, 2019) and Calyxt, Inc. (the "Group").

As of June 30, 2020, Cellectis S.A. held 100% of Cellectis, Inc. and approximately 68,7% of the outstanding ordinary shares of Calyxt, Inc. Cellectis, Inc. held 100% of Cellectis Biologics, Inc.

Until July 25, 2017, Cellectis S.A. held 100% of Calyxt, Inc. On July 25, 2017, Calyxt, Inc. completed its IPO on the Nasdaq raising a total of $64.4 million, before banking commissions and all other fees related to the offering, following the issuance and registration of 8,050,000 shares at $8.00 per share. In May 2018, Calyxt completed a secondary offering of 4,057,500 ADS at a price of $15.00 per ADS, raising gross proceeds of $60.9 million. Cellectis purchased 550,000 Calyxt shares at a price of $15.00 per share. Furthermore, in connection with the acquisition on June 14, 2018 of U.S. bonus shares (RSU) from certain employees and non-employees of Calyxt and Cellectis, Cellectis bought approximately 63,175 ordinary shares of Calyxt at a price of $19.49 per share (closing price published by Nasdaq on June 14, 2018) directly from these employees and non-employees as part of share repurchase transactions dated June 13, 2018. The number of shares offered takes into account the exercise in full by the arranging banks of their over-allotment option and the purchase of $20 millions of shares by Cellectis S.A. Calyxt, Inc. shares are listed on the Nasdaq under the ticker "CLXT".

The Company does not have any branches.

Group activity over the year ended December 31, 2019

R&D

- On February 25, 2019, Cellectis announced the publication of a study in The Journal of Biological Chemistry, identifying Granulocyte Macrophage Colony Stimulating Factor (GMCSF) secreted by

Chimeric Antigen Receptor (CAR) T-cells as a key factor promoting cytokine release syndrome (CRS). The accelerated report leverages these findings to elaborate an innovative engineering strategy that paves the way for developing safer UCART products.

- In March 2019, Cellectis executed a lease agreement for an 82,000 square foot site in Raleigh, North Carolina. This site is being designed to provide GMP manufacturing for clinical supplies and commercial manufacturing upon regulatory approval. In addition, Cellectis is building a 14,000 square foot manufacturing facility in Paris, France. This facility is designed to produce Cellectis' critical raw and starting material supplies for UCART clinical studies and commercial products.
- From April 29, 2019 to May 2, 2019, certain Cellectis employees gave, at the 2019 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, an oral presentation demonstrating the potential of UCARTCS1 as a treatment approach for patients with Multiple Myeloma, and a poster presentation showcasing Cellectis' allogeneic CAR T-cell manufacturing expertise, focusing on a novel, straightforward and efficient strategy to generate Universal CAR T-Cells.
- Cellectis published a paper in November 2019 in Nature Communications that describes a proof-of-concept for rewiring the cell pathway to create highly intelligent T-cells that can recognize cancerous tumors and cause a micro secretion of therapeutic proteins onto these tumors, which ultimately reshapes the tumor microenvironment and improves the T-cells ability to fight cancer.
- On November 20, 2019, Cellectis announced that European Patent EP3004337, which claims a method of preparing T-cells for immunotherapy using the CRISPR-Cas9 system, initially granted on August 2, 2017, has been upheld by the European Patent Office (EPO) following an opposition procedure initiated in May 2018.
- On January 6, 2020, Cellectis announced the publication of a review titled "Off-the-shelf' allogeneic CAR T cells: development and challenges" in Nature Reviews Drug Discovery by Prof. Stéphane Depil, Dr. Philippe Duchateau, Prof. Stephan Grupp, Prof. Ghulam Mufti and Dr. Laurent Poirot. The authors review the opportunities and challenges presented by universal allogeneic CAR T-cell therapies.
- On March 10, 2020, Cellectis announced that a new patent had been granted by the US Patent and Trademark Office (USPTO) to Cellectis for methods of preparing allogeneic T-cells for immunotherapy with CRISPR-Cas9 technology.

Collaborations

- Cellectis announced in October 2019 that it had entered into a manufacturing service agreement with Lonza, covering clinical manufacturing of Cellectis' allogeneic UCART product candidates. Lonza is responsible for implementing Cellectis' manufacturing processes at Lonza's GMP facility in Geleen, Netherlands, as per current Good Manufacturing Practices (cGMP) that meet the highest quality and safety standards outlined by the US Food and Drug Administration (FDA).
- In January 2020, Cellectis and Iovance entered into a research collaboration and exclusive worldwide license agreement whereby Cellectis grants Iovance an exclusive license under certain TALEN® technology in order to develop tumor infiltrating lymphocytes (TIL) that have been genetically edited to create more potent cancer therapeutics. This license enables Iovance Biotherapeutics' use of TALEN® technology addressing multiple gene targets to modify TIL for therapeutic use in several cancer indications. Financial terms of the license include development, regulatory and sales milestone payments from Iovance Biotherapeutics to Cellectis, as well as royalty payments based on net sales of TALEN®-modified TIL products.
- Cellectis and Servier announced the execution of the amendment confirming the terms of the term sheet signed on February 18, 2020. Under this amendment, Cellectis grants Servier an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including rights to UCART19/ALLO-501, and ALLO-501A, an anti-CD19 candidate in which the rituximab recognition domains have been removed, either directly or through its US sublicensee Allogene Therapeutics. In this amendment, financial terms are improved to include an additional USD 27.6 million (EUR 25 million) upfront payment, as well as up to USD 410 million (EUR 370 million) in clinical and commercial milestones. The royalty rate is increased from tiered high single-digit royalties to flat low double-digit royalties based on net sales of products. In addition, Cellectis regains exclusive control over the five undisclosed allogeneic CAR T-cell targets previously covered by the initial agreement.

Clinical Trials

- On October 29, 2019, Cellectis announced the first patient was dosed in the MELANI-01 study, the Phase 1 dose escalation clinical trial evaluating the safety, expansion, persistence and clinical activity of UCARTCS1 in patients with relapsed/refractory multiple myeloma (r/r MM). MELANI-01 is designed to find the safe and optimal therapeutic dose for UCARTCS1.
- On December 2, 2019, Cellectis announced the first patient was dosed in the BALLI-01 study, the Phase 1 dose escalation clinical trial evaluating the safety, expansion, persistence and clinical activity of UCART22 in patients with r/r B-ALL. BALLI-01 is designed to find the safe and optimal therapeutic dose for UCART22.
- On January 15, 2020, Cellectis announced the first patient was dosed in the AMELI-01 study, the Phase 1 dose escalation clinical trial evaluating a new version of our UCART123 product candidate in r/r AML. This trial is part of an Investigational New Drug (IND) from the FDA for a new UCART123 construct and an optimized production process, and is evaluating the safety, expansion, persistence and clinical activity of the product candidate in patients with relapsed/refractory AML. AMELI-01 replaces the first US clinical trial assessing the first version of UCART123 product candidate. AMELI-01 is designed to find the safe and optimal therapeutic dose for UCART123.
- On July 6, 2020, Cellectis announced that the MELANI-01 trial has been placed on clinical hold by the FDA. This clinical hold was initiated following the submission of a safety report regarding one patient enrolled in the MELANI-01 study at dose level two (DL2), with relapsed and refractory multiple myeloma. Cellectis is working closely with the FDA to address the agency's requests including changes to the MELANI-01 clinical protocol designed to enhance patient safety and expect to submit requested information including an amended protocol in due course.

Corporate

- At the combined shareholders meeting held on June 25, 2019 during which more than 68% of voting rights were exercised, Resolutions 1 through 18, 23 and 24 were adopted. Resolutions 19 through 22 and Resolution 25 were rejected.
- On July 22, 2019, William Monteith as Executive Vice President, Technical Operations and Jon Voss as Executive Vice President, Global Quality joined the Executive Committee of the Company, which correspond to the "Chief Operating Decision Maker", or "CODM". On July 22, 2019, Elsy Boglioli left the Company.
- On November 2019, Arthur Stril,Vice President, Corporate Development, joined the Executive Committee of the Company. Arthur is now Chief Business Officer of the Company
- On April 13, 2020, Cellectis appointed of Carrie Brownstein, M.D., to the role of Chief Medical Officer. In Dr. Brownstein's new role, she oversees clinical research and development for Cellectis' UCART clinical trial programs.
- On May 18, 2020, Cellectis announced the appointment of Leopold Bertea, Ph.D., to the role of Senior Vice President of Technical Operations - Europe. His mission is to ensure execution upon Technical Operation milestones in process development, analytical development, external supply, and the GMP Paris manufacturing facility that support the development and production of Cellectis proprietary product candidates.
- On June 29, 2020, Cellectis held its Annual Shareholders' General Meeting in camera at its head office in Paris, France. At the meeting, during which more than 63% of voting rights were exercised, Resolutions 1 through 22, and Resolutions 26 through 28 were adopted. Resolutions 23, 24, 25 and 29 were rejected.
- On July 6, 2020, André Choulika, Ph.D., Cellectis' Chairman and CEO, announced that he will focus all his energy on Cellectis' development activities, and thus, announced his retirement from Calyxt's Board of Directors. Calyxt's Board of Directors has appointed Yves Ribeill, Ph.D., currently a Calyxt Board member, as Chairman. Additionally, Calyxt's Board of Directors appointed Laurent Arthaud, Cellectis' Board member, as a Cellectis designated Director.
- On July 21, 2020, Cellectis announced that Steve Doares, Ph.D., joins Cellectis from Biogen as Senior Vice President of US Manufacturing and Site Head of Raleigh manufacturing plant in NC. Dr. Doares is responsible for the deployment of Cellectis' proprietary state-of-the-art gene-editing cell manufacturing plant in Raleigh, NC.
- On August 5, 2020, Cellectis announced its results for the three-month and six-month periods ended June 30, 2020.

Calyxt, Inc. ("Calyxt")

- On January 3, 2019, Calyxt announced the appointment of William F. (Bill) Koschak as Chief Executive Officer
- On January 23, 2019, Calyxt announced the appointment Kimberly Nelson to its board of directors
- On January 28, 2019, Calyxt announced the appointment of Debra Frimerman as General Counsel.
- On February 19, 2019, Calyxt and Agtegra Cooperative (Agtegra) announced a strategic collaboration to distribute Calyxt High Oleic Soybean.
- On February 19, 2019, Calyxt announced the first commercial sale of its Calyno™ High Oleic Soybean Oil on the US Market.
- On May 6, 2019, Calyxt announced that Dr. Dan Voytas, Co-founder and Chief Science Officer of Calyxt, elected to the National Academy of Sciences.
- On May 15, 2019, Calyxt announced the appointment of Dr. Travis Frey as Chief Technology Officer.
- On June 24, 2019, Calyxt announced the execution of a commercial soybean crushing agreement with Landus Cooperative.
- On September 3, 2019, Calyxt announced the strengthening of its leadership team to support commercial growth opportunities. This move includes notably the appointment of Keith Blanks as Senior Vice President of Sales and Marketing.
- On September 19, 2019, Calyxt announced the execution of a Seed Agreement with Landus Cooperative.
- On September 26, 2019, Calyxt announced six new products candidates at the discovery stage in its R&D pipeline. Four new soybean product candidates comprised of two wellness products, one plant-based protein product, and one sustainability product.
- On December 3, 2019, Calyxt announced the appointment of Vince Restucci as Vice President of Agronomy Services.
- On December 16, 2019, Calyxt announced a collaboration with Central Valley Ag to expand Grower Network.
- On January 23, 2020, Calyxt announced the appointment of Bobby Williams as Gene Editing Director to Expand Innovation and Product Pipeline.
- On February 7, 2020, Calyxt announced the achievement of 2020 Soybean Contracted Acreage Goal of 100,00 acres.
- On April 7, 2020, Calyxt has licensed new enabling technology from University of Minnesota for greater efficiency in gene edited plants.
- On April 30, 2020, Calyxt announced the launch of consumer e-commerce channel for Calyno® Premium Cooking Oil.
- On June 3, 2020, Calyxt announced that its High Oleic Low Linoleic Soybean is deemed non-regulated by the US Department of Agriculture (USDA).
- On July 6, 2020, Calyxt announced the retirement of André Choulika from the Calyxt's board of directors, the appointment of Yves Ribeill as Chairman of the board of directors and the appointment of Laurent Arthaud as director.
- On August 5, 2020, Calyxt Reported Second Quarter 2020 Financial Results and announced focusing on go-to-market strategies to optimize TALEN technology platform and accelerate trajectory to positive free cash flow.

Group Headcount

As of December 31, 2019, the average headcount for the group was 205 employees, and 149 employees as of December 31, 2018.

Our Strategy

Our strategy is to leverage the transformative potential of our unique gene-editing technologies and expertise through our cell therapy platform.

The key elements of our strategy are to:

- Advance its self-owned allogeneic UCART portfolio of product candidates up to the Biologics License Application (BLA) and commercialize them;
- Build a self-owned manufacturing network to produce commercial-grade UCART products for clinical use, as well as critical raw and starting material of the UCART product candidates;
- Build a self-owned manufacturing network to produce commercial-grade UCART products for clinical use, as well as critical raw and starting material of the UCART product candidates;
- Structure a commercial launch plan for our wholly-owned product candidates;
- Prepare its next innovative project through an hematopoietic stem cells (HSC) platform;
- Utilize its gene-editing platform to develop and commercialize products, through our 68.7% (as of June 30, 2020) ownership in Calyxt, for the multibillion dollar agricultural-biotechnology market. Calyxt is applying patented breeding technology, including our gene-editing technologies to create products with human health benefits and that are more sustainable than others available on the market today. By selecting and inactivating target genes in selected crops, we believe Calyxt can produce unique variants with consumer benefits. Calyxt is developing a pipeline of traits for soybeans, wheat, alfalfa, potatoes, canola, hemp, oats, and other crops.

--ooOoo--

REQUEST FOR THE SENDING OF ADDITIONAL DOCUMENTS

In the context of the Covid-19 epidemic and taking into account the uncertainty surrounding the postal delays, the Company wishes to favor, when possible, the electronic means of communication, therefore recommends to the shareholders to request documents to be sent by email to the address they will indicate below.

The undersigned:

NAME AND FIRST NAME _____

ADDRESS_____

EMAIL ADDRESS_____

owner of _____ share(s) in the:

- nominative form,

- bearer form, registered with: _____ **(1)**

acknowledge receipt of the documents relating to the combined ordinary and extraordinary general meeting of the shareholders to be held on **November 4th, 2020** referred into Article R. 225-81 of the commercial code,

request **CELLECTIS** to provide, for the said meeting, the documents referred to in Article R. 225-83 of the French commercial code as follows:

☐ Printed documents
☐ Electronic files to the email address above

Executed in

On

Signature:

NOTA: In accordance with the provisions of Article R 225-88 paragraph 3 of the French commercial code, the shareholders holding shares in the nominative form may, by a single request, obtain from the Company the documents referred to in Articles R. 225-81 and R 225-83 of that code, for each subsequent shareholders' meeting. If the shareholder wishes to benefit from this option, mention shall be made on this request.

(1) indication of the bank, financial institution or online broker, etc. account holder (the applicant must prove its shareholder status by sending a certificate of holding issued by the authorized intermediary).